2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Wei-Kuang Chi

Session 10 –New Frontiers in Therapeutics
Date: 24 July (Friday) 09:00 – 10:30 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform


Wei-Kuang Chi

Vice President, R&D,
Development Center for Biotechnology



 

Dr. Wei-Kuang Chi, Vice President Since November 20, 2019 of the Development Center for Biotechnology (DCB), obtained his M.S in Engineering and Ph.D. in Chemical Engineering from the University of Pennsylvania, Philadelphia, USA. Dr. Chi has over 30 years of experience in biotechnology process development. He established DCB’s multi-product 500 L mammalian cell culture and 100 L microbial fermentation CGMP Biopharmaceutical Pilot Plant Facility (BPPF) and certified by Taiwan Department of Health (DOH) on December 2005 and received DMF with USA FDA on March 2006. The CGMP BPPF has been spun-off on 2013 into private sector to provide CDMO service on a broader scale. Dr. Chi’s new responsibility will focus on new drug R&D, international collaboration, novel bioengineering technology, CAR-T/iPSC development, application of deep learning/AI on drug discovery and /biomanufacturing process


Speech title & Synopsis

A NEW Toolbox for Oncology Therapies

- DCB introduction
- Site-Specific ADC Platform (Trimannosyl Conjugation)
- Immuno-Oncology Toolbox
- CAR-T (Chimeric Antigen Receptor T Cells) Platform for Liquid and Solid Tumor TreatmentPROTAC (PROteolysis TArgeting Chimeras) Toolbox